Literature DB >> 14525800

Roles of FcgammaRIIB in nasal eosinophilia and IgE production in murine allergic rhinitis.

Tohru Watanabe1, Mitsuhiro Okano, Hisashi Hattori, Tadashi Yoshino, Nobuaki Ohno, Nobuo Ohta, Yuji Sugata, Yorihisa Orita, Toshiyuki Takai, Kazunori Nishizaki.   

Abstract

The low-affinity IgG Fc receptor, FcgammaRIIB, displays inhibitory potential in experimental models such as autoimmune diseases. However, whether this receptor is involved in the onset of allergic diseases remains unknown. This study examines the role of FcgammaRIIB in the initiation of allergic rhinitis in mice. Repeated intranasal sensitization with Schistosoma mansoni egg antigen (SEA) induced SEA-specific IgE and marked nasal eosinophilia in high-responder BALB/c mice. FcgammaRIIB gene-deficient (-/-) BALB/c mice displayed severe eosinophilia compared with that of wild-type counterparts. However, FcgammaRIIB -/- mice conversely produced less SEA-specific IgE. The production of interleukin (IL)-4 but not of IL-5 or IFN-gamma by nasal mononuclear cells was also decreased in FcgammaRIIB -/- mice, suggesting that the exacerbation of nasal eosinophila in FcgammaRIIB -/- mice is independent of the local IL-5 levels. The findings in low responder C57BL/6 mice were similar. In addition, nasal eosinophilia in FcgammaRIIB -/- mice passively sensitized with SEA was exacerbated, and conversely, specific IgE production was inhibited after a nasal challenge. These results suggest that FcgammaRIIB plays a regulatory role in the initiation of allergic rhinitis that is independent of either mouse strain or type of sensitization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14525800     DOI: 10.1164/rccm.200302-239OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  7 in total

1.  Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivity.

Authors:  Oliver T Burton; Stephanie L Logsdon; Joseph S Zhou; Jaciel Medina-Tamayo; Azza Abdel-Gadir; Magali Noval Rivas; Kyle J Koleoglou; Talal A Chatila; Lynda C Schneider; Rima Rachid; Dale T Umetsu; Hans C Oettgen
Journal:  J Allergy Clin Immunol       Date:  2014-07-16       Impact factor: 10.793

2.  Bronchial Vascular Remodeling Is Attenuated by Anti-IL-17 in Asthmatic Responses Exacerbated by LPS.

Authors:  Leandro do Nascimento Camargo; Tabata Maruyama Dos Santos; Felipp Costa Pinto de Andrade; Silvia Fukuzaki; Fernanda Degobbi Tenorio Quirino Dos Santos Lopes; Milton de Arruda Martins; Carla Máximo Prado; Edna Aparecida Leick; Renato Fraga Righetti; Iolanda de Fátima Lopes Calvo Tibério
Journal:  Front Pharmacol       Date:  2020-09-04       Impact factor: 5.810

3.  FcgammaRIIb inhibits allergic lung inflammation in a murine model of allergic asthma.

Authors:  Nilesh Dharajiya; Swapnil V Vaidya; Hiroki Murai; Victor Cardenas; Alexander Kurosky; Istvan Boldogh; Sanjiv A Sur
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

4.  Contribution of Fcγ receptors to human respiratory syncytial virus pathogenesis and the impairment of T-cell activation by dendritic cells.

Authors:  Roberto S Gómez; Bruno A Ramirez; Pablo F Céspedes; Kelly M Cautivo; Sebastián A Riquelme; Carolina E Prado; Pablo A González; Alexis M Kalergis
Journal:  Immunology       Date:  2015-11-06       Impact factor: 7.397

5.  B cell antigen presentation promotes Th2 responses and immunopathology during chronic allergic lung disease.

Authors:  Dennis M Lindell; Aaron A Berlin; Matthew A Schaller; Nicholas W Lukacs
Journal:  PLoS One       Date:  2008-09-03       Impact factor: 3.240

6.  Functional Fcgamma receptor polymorphisms are associated with human allergy.

Authors:  Jianming Wu; Rui Lin; Jinhai Huang; Weihua Guan; William S Oetting; P Sriramarao; Malcolm N Blumenthal
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

7.  Atopic dermatitis and association of risk for primary immune thrombocytopenia and autoimmune diseases among children: A nationwide population-based cohort study.

Authors:  Chang-Ching Wei; Cheng-Li Lin; Te-Chun Shen; Jeng-Dau Tsai
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.